International Social-Impact Award Finalist: TGen's social media analysis on platform.org
The Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based non-profit organisation, is making significant strides in the fight against Alzheimer's disease with its groundbreaking online research platform, "Our Platform." This digital infrastructure is designed to facilitate advanced studies in neurodegenerative diseases, including Alzheimer's.
With more than 28,000 volunteers already taking part and over 2.3 thousand shares and 130 thousand views on the news article about the project, TGen's initiative is gaining traction. The goal of the project is to gather results from as many as 1 million participants to better understand Alzheimer's disease.
TGen's Senior Science Writer, Steve Yozwiak, can be reached at 602-343-8704 or [email protected] for more information about the project.
Alzheimer's disease, a socioeconomic epidemic that significantly impacts society, affects more than 5 million Americans. It is the 6th leading cause of death in the U.S. and costs the nation more than $200 billion to treat annually.
TGen's work on the platform contributes to the efficiency and effectiveness of the translational process. The project integrates diverse datasets, including genomics, biomarkers, and imaging, to help identify early signals of Alzheimer's progression. It also employs artificial intelligence (AI) and machine learning algorithms to detect subtle brain activity patterns or genetic markers indicative of Alzheimer's and related dementias.
The platform enables faster, more precise diagnosis through data-driven insights, bridging research findings and clinical practice. It also supports biomarker discovery and validation to improve screening and therapeutic target identification.
The 5th annual CLASSY Awards, the largest social impact awards ceremony in the United States, will be held on May 3, 2014, at the Marriott Marquis in San Diego. Top leaders from the social sector will convene at the CLASSY Awards to collaborate on solving social problems. This year, TGen's platform.org project is a finalist for the CLASSY Awards, an annual social impact celebration that recognizes organisations that promote social progress and encourages conversations around social problems and solutions.
The platform.org project by TGen is an innovative social-media investigation of Alzheimer's disease. It is a web-based scientific study of how our brain learns and remembers items of information. TGen's work with this platform aligns with broader trends in Alzheimer's research where integrated data platforms and AI tools are transforming diagnosis and treatment strategies.
For more information about TGen and its work, visit www.tgen.org.
[1] Mayo Clinic’s StateViewer tool:
- The science of neurogenomics, a key aspect of TGen's work, is proving instrumental in the fight against Alzheimer's disease, as demonstrated by their groundbreaking online research platform, "Our Platform."
- The advancements in health-and-wellness, specifically related to Alzheimer's disease, have been recognized by the 5th annual CLASSY Awards, with TGen's platform.org project being a finalist for the event.
- TGen's platform not only integrates diverse datasets in neurodegenerative diseases but also employs therapies-and-treatments like artificial intelligence (AI) and machine learning algorithms to detect early signs of Alzheimer's.
- Alzheimer's disease, a significant socioeconomic issue, is affecting more than 5 million Americans, making the work in environmental-science, such as TGen's, crucial for understanding, preventing, and managing this disease.
- The impact of climate-change on mental-health, particularly regarding its potential effects on aging and Alzheimer's disease, is a growing concern for medicare and policymakers worldwide.
